Optimal therapy of genotype-2 chronic hepatitis C: what's new?

Abstract

The standard of care (SOC) for the treatment of HCV genotype 2 (HCV-2) was pegylated interferon alpha plus ribavirin (PEG-IFN/RBV) at weight-based doses for a response-guided duration. The launches of sofosbuvir and daclatasvir in 2014 have resulted in new, better tolerated and shorter treatment. The combination of sofosbuvir and RBV for 12 weeks appears to be the new SOC in both European and American guidelines. The cost and therefore the access to this treatment remains a problem in many countries because of major economic constraints. For the few more difficult-to-treat patients, a combination of direct acting antivirals may be suitable and is being studied in ongoing trials. Because of rapidly changing treatment recommendations, the decision to treat HCV-2 patients with currently approved drugs or to wait until a better option is available in the future, must be made according to the stage of fibrosis.

DOI: 10.1111/liv.12711

Cite this paper

@article{Bourlire2015OptimalTO, title={Optimal therapy of genotype-2 chronic hepatitis C: what's new?}, author={Marc Bourli{\'e}re and Souad Benali and Christelle Ansaldi and Gaelle Le Folgoc and Aur{\'e}lie Riso and Laurence Lecomte}, journal={Liver international : official journal of the International Association for the Study of the Liver}, year={2015}, volume={35 Suppl 1}, pages={21-6} }